Africa contributes less than 3% of global genome sequencing data, a gap that limits medical research and treatment for diseases prevalent on the continent. Determined to change this, Dr. Abasi Ene-Obong — founder of 54gene — launched Syndicate Bio in September 2023 to accelerate genomics and precision medicine across Africa. The company recently unveiled its state-of-the-art sequencing laboratory in Lagos, which aims to make advanced genetic testing accessible and affordable to Africans. Its flagship service, Direct by Syndicate Bio, provides AI-powered genetic analysis to deliver actionable health insights for patients and healthcare providers.
Through partnerships with governments, research institutions, and global medical centers, Syndicate Bio is building a comprehensive ecosystem to integrate genomics into clinical care. Its Direct Nigeria Precision Medicine Network (DNPMN) connects local hospitals with international partners such as Roswell Park Comprehensive Cancer Center, Lakeshore Cancer Centre, and Redus Centre for Digestive Health. The initiative supports collaboration on complex cancer cases, second opinions, and knowledge exchange. Dr. Sai Yendamuri of Roswell Park said the partnership reflects “a shared commitment to making precision medicine accessible to underserved populations across Africa.”
Direct’s suite of tests focuses on oncology, pharmacogenomics, and hereditary conditions, addressing urgent healthcare needs in Nigeria — a country with over 260,000 new cancer cases as of 2022 but only 27 treatment centers. Its lab can analyze more than 300 genes linked to cancers such as breast, ovarian, and prostate, while also identifying 90 inherited disorders. Other services include drug response testing, sickle cell screening, and non-invasive prenatal testing. Samples collected from over 20 partner labs nationwide are sequenced locally, with AI analyzing genetic data to generate clinical reports and genetic counseling for patients.
Dr. Ene-Obong emphasized that Africa’s genetic diversity offers a unique opportunity to reshape global medicine. By building one of the continent’s largest genomic datasets, Syndicate Bio seeks to empower healthcare systems with data-driven insights, influence health policy, and ensure Africans benefit from treatments tailored to their genetic realities. “With Direct, we’re harnessing Nigeria’s rich genetic diversity to improve care for Nigerians and the diaspora,” he said. “Ultimately, this is about ensuring Africa has a strong voice in the future of global medicine.